Company News: Page (1) of 1 - 05/16/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Expert group to review evidence for use of medical cannabis for employer plans

(May 16, 2018)

Recommendations for covering medical cannabis will be available to employers

TORONTO, May 16, 2018 (GLOBE NEWSWIRE) -- Today, Reformulary Group, Canada’s leading, independent drug plan management company, announced its Cannabis Formulary Committee, which will review the best available evidence for medical cannabis and provide expert opinions and criteria for its use in specific indications. 

The Cannabis Formulary Committee will recommend specific medical uses and develop criteria for appropriate use, lines of therapy, specific strains, form, grams per indication, mode of consumption and quantity limits. The Committee will advise on the creation of a registry to capture real-world patient-reported data. Data will be used to adapt the formulary where necessary and help patients and doctors make evidence-based decisions.   

“For Canadian employers that choose to cover medical cannabis, our cannabis formulary – called Cannabis Standard – will be an essential product to access the best available evidence and expert advice,” said Helen Stevenson, Reformulary Group founder and CEO. “By subscribing, an employer can be confident that their employees are following expert criteria on how and what to consume when it comes to medical cannabis and specific indications.”



The Cannabis Standard formulary will be available to employers on a subscription basis. Reformulary Group has established and will continue to develop partnerships with several Licensed Producers to ensure employers and individuals using the formulary receive preferred prices and access to customer care programs. These partnerships will also support the development of the registry.

Reformulary’s Cannabis Formulary Committee is comprised of experts who specialize in medical cannabis and/or evidence-based reviews, including:

  • Dr Danial Schecter, family physician and founder of Cannabinoid Medical Clinic
  • Dr Paul Daeninck, medical oncologist at CancerCare Manitoba and President of the Board, Canadian Consortium for the Investigation of Cannabinoids (CCIC)
  • Dr Paul Oh, Medical Director, Cardiac Rehab and Secondary Prevention Program at Toronto Rehabilitation Institute, and Chair, Reformulary Expert Committee
  • Mike Boivin, clinical pharmacist, CME developer, founder CommPharm Consulting, with expertise in medical cannabis

About Reformulary Group
Reformulary Group is a healthcare company, founded in Toronto in 2011. The company’s most notable innovation is its proprietary formulary – the Reformulary® – which it sells on a subscription basis to Canadian employers. The Reformulary is curated based on the trusted advice of an independent panel of doctors and pharmacists. Reformulary Group CEO, Helen Stevenson started the company in 2011. The former Executive Officer, Ontario Public Drug Programs, and Assistant Deputy Minister of Health, Stevenson and her team saved Ontario taxpayers $1.5 billion. Plans powered by Reformulary® achieve significant savings and through the DrugFinder™ app, help people make smart drug choices and take control of their health.  

www.reformulary.com

Media Contact:
Alex Cerelli, MAVERICK
O: 416.640.5525 x 238
M: 905.864.5530
E: alexc@wearemaverick.com


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

Our Privacy Policy --- @ Copyright, 2017 Digital Media Online, All Rights Reserved